RxDoctor Payments Data

Ignacio de Cicco, MD

Internal Medicine · Wichita, KSNPI 1770998973

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 19 payments — averaging $74.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$976
  • Sanofi-aventis U.S. LLC$125
  • Boston Scientific$113
  • Medtronic$75
  • EKOS Corporation$65
  • United Therapeutics Corporation$22
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$1,23788%
  • Education$17012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,407 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$170,462
Medicare patients
583
Services billed
2,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$349,245
XareltoRivaroxaban49$48,002
EntrestoSacubitril/Valsartan42$45,793
MounjaroTirzepatide21$22,451
VascepaIcosapent Ethyl37$19,586
FarxigaDapagliflozin Propanediol12$6,872
Bumetanide154$4,916
Metoprolol Succinate566$4,882
Atorvastatin Calcium704$4,536
Potassium Chloride195$4,155
Amlodipine Besylate338$1,525
Losartan Potassium201$1,475
FenofibrateFenofibrate Nanocrystallized60$1,254
Ranolazine ErRanolazine12$1,178
Carvedilol263$1,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$16$48,00249 claims
AstraZenecaFarxiga$14$6,87212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →